Search
Roivant Sciences Ltd
ROIVAdd to Watchlist
32.160USD
+0.730+2.32%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
22.82BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Roivant Sciences Ltd is 8.77, ranking 8 out of 157 in the Pharmaceuticals industry. The average price target is 24.00, with a high of 29.00 and a low of 20.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
38.591
Target Price
+22.78%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Roivant Sciences Ltd
ROIV
13
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Roivant Sciences Ltd's expected revenue for the next quarter?
Roivant Sciences Ltd's expected revenue is 2.12M.
What is Roivant Sciences Ltd's price target?
Analysts forecast that Roivant Sciences Ltd's price target is USD 24.00, with the highest forecast at USD 29.00 and the lowest forecast at USD 20.00.
How have Roivant Sciences LtdROIV's recent earnings per share performed?
The market expectation was USD 0.42, while Roivant Sciences LtdROIV's earnings per share (EPS) for the previous quarter was USD -0.38. EPS for the next quarter is expected at USD -0.31.
What is the analyst rating for Roivant Sciences Ltd?
Based on the ratings of Roivant Sciences Ltd's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
